Following on from information provided to NICE by the company in April 2019, the appraisal of Pembrolizumab for treated oesophageal or gastro-oesophageal junction cancer [ID1357] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
Status | Discontinued |
Technology type | Medicine |
Decision | Selected |
Process | TA |
ID number | 1357 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Stakeholders
Companies sponsors | Merck Sharp & Dohme (pembrolizumab) |
Others | Department for Health and Social Care |
NHS England | |
Welsh Government | |
Professional groups | Association of Cancer Physicians |
Cancer Research UK | |
Royal College of Physicians | |
Royal College of Radiologists | |
Comparator companies | Accord Healthcare (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement) |
Actavis UK (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement) | |
Celgene (paclitaxel) (not signed confidentiality agreement) | |
Hospira UK (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement) | |
Medac GmbH (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement) | |
Pfizer Ltd (irinotecan) (not signed confidentiality agreement) | |
Sanofi (docetaxel) (not signed confidentiality agreement) | |
Seacross Pharmaceuticals (docetaxel, irinotecan) (not signed confidentiality agreement) | |
Shire Pharmaceuticals (irinotecan) (not signed confidentiality agreement) | |
General commentators | All Wales Therapeutic and Toxicology Centre |
British National Formulary | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Scottish Medicines Consortium | |
Welsh Health Specialised Services Committee | |
Relevant research groups | Institute of Cancer Research |
National Cancer Research Institute |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
08 November 2022 | Discontinued. Following on from information provided to NICE by the company in April 2019, the appraisal of Pembrolizumab for treated oesophageal or gastro-oesophageal junction cancer [ID1357] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
16 September 2019 | The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
11 April 2019 | Suspended. Appraisal suspended |
07 March 2019 | Invitation to participate |
04 April 2018 - 02 May 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
01 March 2017 | In progress. DH Referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual